EDGAR Filing Documents for 0001176256-11-000215

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001176256-11-000215

Filing Date

2011-03-15

Accepted

2011-03-15 13:34:47

Documents

Period of Report

2010-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2010	nymox20f101231.htm	20-F	1610121
2	SOX SECTION 302 CEO CERTIFICATION	exhibit12-a.htm	EX-12.A	6435
3	SOX SECTION 302 CFO CERTIFICATION	exhibit12-b.htm	EX-12.B	6543
4	SOX SECTION 906 CEO CERTIFICATION	exhibit13-a.htm	EX-13.A	2172
5	SOX SECTION 906 CFO CERTIFICATION	exhibit13-b.htm	EX-13.B	2130
6		kpmg.jpg	GRAPHIC	2208
	Complete submission text file	0001176256-11-000215.txt		1631595

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 5143323222

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 11687996
SIC: 2835 In Vitro & In Vivo Diagnostic Substances